| 4.72 0.065 (1.4%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.3 | 1-year : | 7.03 |
| Resists | First : | 5.4 | Second : | 6.01 |
| Pivot price | 4.91  |
|||
| Supports | First : | 4.4 | Second : | 3.66 |
| MAs | MA(5) : | 4.77 |
MA(20) : | 5.08 |
| MA(100) : | 4.51 |
MA(250) : | 3.11 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.9 |
D(3) : | 33.6 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 6.01 | Low : | 1.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TSHA ] has closed above bottom band by 27.3%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.74 - 4.75 | 4.75 - 4.77 |
| Low: | 4.45 - 4.47 | 4.47 - 4.49 |
| Close: | 4.68 - 4.72 | 4.72 - 4.75 |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Fri, 23 Jan 2026
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Fri, 23 Jan 2026
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.2% - What's Next? - MarketBeat
Thu, 22 Jan 2026
Taysha Gene Therapies commences underwritten public offering - MSN
Fri, 16 Jan 2026
A Look At Taysha Gene Therapies (TSHA) Valuation After Key TSHA-102 Rett Syndrome Trial Milestones - simplywall.st
Wed, 14 Jan 2026
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects - Yahoo Finance
Tue, 06 Jan 2026
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 274 (M) |
| Held by Insiders | 1.7659e+008 (%) |
| Held by Institutions | 11 (%) |
| Shares Short | 49,040 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0098e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 618.5 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 6.31e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -64.94 |
| EBITDA (p.s.) | 6.31e+006 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -85 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.08 |
| Price to Cash Flow | 5.89 |
| Dividend | 0 |
| Forward Dividend | 5.603e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|